Skip Navigation

Technology Transfer and Intellectual Property

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Awards and Success Stories

Two NIAID Technologies Featured in 2015 FLC Planner

atomic level protein structure of the antibody VRC01 binding to HIV
Colorized scanning electron micrograph of filamentous Ebola virus particles (blue) budding from a chronically infected VERO E6 cell (yellow-green). Credit: NIAID

The 2015 Planner for the Federal Laboratories Consortium (FLC) will feature two NIAID technologies. One is an Ebola vaccine antibody study from Heinz Feldmann, M.D., Ph.D., chief of the Laboratory of Virology at the NIAID Rocky Mountain Laboraories. NIAID researchers and colleagues determined that the level of antibody production was the critical factor for protection in experimental vaccines against Ebola virus.

The other featured technology comes from NIAID Director Anthony S. Fauci, M.D., discovering the source of the memory B cells that produce rare, neutralizing HIV antibodies in a subset of early infected patients. The findings augment the current understanding of how HIV disease develops and has implications for the timing of treatment.

There were 118 submissions for the 2015 FLC Planner, which will go out to over 12,000 FLC members, as well as members of industry and academia. The planner supports the FLC mission to promote and facilitate the rapid movement of federal laboratory research results and technologies into the mainstream of the U.S. economy.

See the June entry of the 2015 FLC Planner featuring an NIAID Ebola vaccine antibody study (PDF).

See the planner's Featured Technologies showcasing NIAID's Timing of HIV Treatments (PDF).

 
 
 
 
 
 
 
 
 
 

Last Updated October 10, 2014